BL-M14D1

DRUG3 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Conditions

Extensive-stage Small-cell Lung CancerLocally Advanced Extrapulmonary Neuroendocrine CarcinomaLocally Advanced Large Cell Neuroendocrine Carcinoma of the LungLocally Advanced Merkel Cell CarcinomaLocally Advanced Neuroendocrine Prostate CancerLocally Advanced Poorly Differentiated Gastroenteropancreatic NeuroendocrineMetastatic Advanced Merkel Cell CarcinomaMetastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Phase 1

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

RecruitingNCT06505824

Sichuan Baili Pharmaceutical Co., Ltd.Neuroendocrine Tumors, Small Cell Lung Cancer

Start: 2024-08-02End: 2026-08-31Target: 22Updated: 2025-09-18

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

RecruitingNCT07080242

SystImmune Inc.Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Merkel Cell Carcinoma +8

Start: 2025-04-28End: 2027-12-31Target: 120Updated: 2026-09-16

Phase 2

A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

RecruitingNCT07654400

Sichuan Baili Pharmaceutical Co., Ltd.Extensive-stage Small-cell Lung Cancer

Start: 2026-07-09End: 2027-12-01Target: 36Updated: 2026-08-25

Related Papers

Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors.

Journal of Clinical Oncology2026-05-27